# US 2013/0158249 A1 · Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158249 A1
- Document ID: US20130158249A1
- Status: Published application
- Kind: A1
- Application number: 13/817,820
- Filed: 2011-08-19
- Published: 2013-06-20
- Earliest claimed: 2010-08-20
- Assignees: SeNA Research, Inc.
- Inventors: Zhen Huang
- Web page: https://patentgrep.com/patent/US20130158249A1

## CPC

- C07H 1/04: Introducing polyphosphoric acid radicals
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Disclosed are compounds of nucleoside 5′-triphosphates of formula (I), or derivatives thereof, or pharmaceutically acceptable salts of said nucleoside 5′-triphosphates or said derivatives, wherein the Base of formula (I) is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase; R1 is H or OH, R2 is H or OH, X is independently selected from the group consisting of O, S and Se; and Y is independently selected from the group consisting of O, B (borano, or BH3), S, and Se. Also disclosed are processes of preparing the compounds of formula (I), said process comprising steps according to Scheme A:

## Claims

### Claim 1

A process of preparing a nucleoside 5′-triphosphate of formula (I), or a derivative thereof, or a pharmaceutically acceptable salt of said nucleoside 5′-triphosphate or said derivative,
wherein the Base of formula (I) is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase; R1 is H or OH, R2 is H or OH, X is independently selected from the group consisting of O, S and Se; and Y is independently selected from the group consisting of O, B (borano, or BH3), S, and Se;
comprising steps according to Scheme A:
wherein in step (a), salicyl phosphorochloridite 1 or a derivative of said salicyl phosphorochloridite 1 is reacted with an suitable pyrophosphate reagent or a derivative of said pyrophosphate reagent under a suitable solvent and suitable temperature to provide a cyclic phosphite intermediate 2 (P2,P3-dioxo-P1-(salicyl)cyclotriphosphite), and then said intermediate 2 is reacted with a nucleoside under a suitable solvent and suitable temperature to provide an intermediate 3 (P2,P3-dioxo-P1-5′-(nucleosidyl-5′-O-)cyclotriphosphite); and in step (b), said intermediate 3 is converted to product 4 (nucleoside 5′-triphosphate) via oxidation with suitable oxidative reagent and then hydrolysis with or without a suitable base.

### Claim 2 (depends on 1)

The process of claim 1, wherein said nucleoside 5′-triphosphate is 2′-deoxynucleoside 5′-triphosphate (dNTPs) of formula (II):

### Claim 3 (depends on 1)

The process of claim 1, wherein in the conversion of compound 1 to said intermediate 2 of step (a), said suitable pyrophosphate reagent is tributyl ammonium pyrophosphate, said suitable solvent is DMF, and said suitable temperature is from about 0.0° C. to about 100° C.; and wherein in the conversion of said intermediate 2 to said intermediate 3 of step (a), said suitable solvent is DMF and said suitable temperature is from about 0.0° C. to about 100° C.; and wherein in the conversion of said intermediate 3 to said product 4 of step (b), said suitable oxidative reagent is iodine and said suitable base is pyridine.

### Claim 4 (depends on 1)

The process of claim 1, wherein said process is carried out according to Scheme B,

### Claim 5 (depends on 1)

The process of claim 1, wherein said process is a one-pot reaction where no isolation or purification of said intermediates is needed and said product can be isolated or purified at the end of said process.

### Claim 6 (depends on 1)

The process of claim 1, wherein said process involves generation of an in situ, selective phosphorylating reagent (intermediate 2) that reacts selectively with the 5′-hydroxyl group of said nucleoside and subsequently forms said nucleoside 5′-triphosphate in one-pot.

### Claim 7 (depends on 1)

The process of claim 1, wherein said process does not involve protection and/or deprotection of amino and/or hydroxyl groups of said nucleoside.

### Claim 8 (depends on 1)

The process of claim 1, wherein the formation of said intermediate 2 involves two nucleophilic displacement reactions: (i) a nucleophilic attack at the phosphorous center of said salicyl phosphorochloridite 1 exerted by the oxide group of the pyrophosphate displacing the chloride ion, and followed by (ii) a displacement of the carboxylate group upon a second attack of another oxide of pyrophosphate which provides the said intermediate 2.

### Claim 9 (depends on 1)

The process of claim 1, wherein the conversion of said intermediate 2 to said intermediate 3 is achieved where the 5′-hydroxyl group of said nucleoside exerts a nucleophilic attack on the phosphorous center of said intermediate 2, following ring opening of said intermediate 2 and subsequent displacement of the phenolic group during the intramolecular reaction to provide said intermediate 3.

### Claim 10 (depends on 1)

The process of claim 1, wherein purified yield of said product from said process is from about 80% to about 100%.

### Claim 11 (depends on 1)

The process of claim 1, wherein said derivative is an oligonucleotide, DNA or RNA.

### Claim 12 (depends on 1)

The process of claim 1, wherein said nucleoside 5′-triphosphate is a natural nucleoside 5′-triphosphate or a modified nucleoside 5′-triphosphate and can be incorporated into DNAs by DNA polymerase or incorporated into RNAs by RNA polymerase.

### Claim 13 (depends on 1)

The process of claim 1, wherein said nucleoside 5′-triphosphate is a substrate for DNA polymerase.

### Claim 14 (depends on 1)

The process of claim 1, wherein said process can be applied to synthesize a base-modified nucleoside 5′-triphosphate.

### Claim 15 (depends on 1)

The process of claim 1, wherein said base-modified nucleoside 5′-triphosphate has a base with a structure of formula (III),

### Claim 16 (depends on 1)

The process of claim 1, wherein said process can be applied to the synthesis of alpha-modified nucleoside 5′-triphosphate, beta-modified nucleoside 5′-triphosphate or gamma-modified nucleoside 5′-triphosphate.

### Claim 17 (depends on 16)

The process of claim 16, wherein said alpha-modified nucleoside 5′-triphosphate is nucleoside 5′-(α-P-thiotriphosphates), nucleoside 5′-(α-P-selenotriphosphates), or nucleoside 5′-(α-P-boranotriphosphates); said beta-modified nucleoside 5′-triphosphate is nucleoside 5′-(β-P-thiotriphosphates), nucleoside 5′-(β-P-selenotriphosphates), or nucleoside 5′-(β-P-boranotriphosphates); said gamma-modified nucleoside 5′-triphosphate is nucleoside 5′-(γ-P-thiotriphosphates), nucleoside 5′-(γ-P-selenotriphosphates), or nucleoside 5′-(γ-P-boranotriphosphates).

### Claim 18 (depends on 17)

The process of claim 17, wherein said alpha-modified nucleoside 5′-triphosphate is synthesized via oxidation of said intermediate 3 by a suitable sulfur, selenium or borane reagent.

### Claim 19 (depends on 18)

The process of claim 18, wherein said suitable sulfur, selenium or borane reagent is 3H-benzo[d][1,2]thiaselenol-3-one.

### Claim 20 (depends on 16)

The process of claim 16, wherein said alpha-modified nucleoside 5′-triphosphate is nucleoside 5′-(P-seleno)triphosphates (NTPαSe).

### Claim 21 (depends on 20)

The process of claim 20, wherein said nucleoside 5′-(P-seleno)triphosphates (NTPαSe) is synthesized according to Scheme D,
wherein the Base is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase.

### Claim 22

A compound of nucleoside 5′-triphosphate of formula (I), or a derivative thereof, or a pharmaceutically acceptable salt of said nucleoside 5′-triphosphate or said derivative,
wherein the Base of formula (I) is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase; R1 is H or OH, R2 is H or OH, X is independently selected from the group consisting of O, S and Se; and Y is independently selected from the group consisting of O, B (borano, or BH3), S, and Se.

### Claim 23 (depends on 22)

The compound of claim 22, wherein said compound is an alpha-modified nucleoside 5′-triphosphate selected from the group consisting of nucleoside 5′-(α-P-thiotriphosphates), nucleoside 5′-(α-P-selenotriphosphates) and nucleoside 5′-(α-P-boranotriphosphates); or a beta-modified nucleoside 5′-triphosphate selected from the group consisting of nucleoside 5′-(β-P-thiotriphosphates), nucleoside 5′-(β-P-selenotriphosphates) and nucleoside 5′-(β-P-boranotriphosphates).

### Claim 24 (depends on 22)

The compound of claim 22, wherein said compound is a gamma-modified nucleoside 5′-triphosphate selected from the group consisting of nucleoside 5′-(γ-P-thiotriphosphates), nucleoside 5′-(γ-P-selenotriphosphates) and nucleoside 5′-(γ-P-boranotriphosphates).

### Claim 25 (depends on 22)

The compound claim 22, wherein said compound is an alpha-, beta-modified nucleoside 5′-triphosphate.

### Claim 26 (depends on 22)

The compound claim 22, wherein said compound is a beta-, gamma-modified nucleoside 5′-triphosphate.

### Claim 27 (depends on 22)

The compound claim 22, wherein said compound is an alpha-, gamma-modified nucleoside 5′-triphosphate.

### Claim 28 (depends on 22)

The compound claim 22, wherein said compound is an alpha-, beta-, gamma-modified nucleoside 5′-triphosphate.

### Claim 29 (depends on 22)

The compound of claim 22, wherein said compound is selected from the group consisting of nucleoside 5′-(α-P-seleno, β-P-selenotriphosphates), nucleoside 5′-(α-P-seleno, γ-P-selenotriphosphates), nucleoside 5′-β-P-seleno, γ-P-selenotriphosphates), and nucleoside 5′-(α-P-seleno, β-P-seleno, γ-P-selenotriphosphates).

### Claim 30 (depends on 22)

A composition comprising the compound according to claim 22.
